Abd‐Elsalam 2016.

Methods	Randomised clinical trial
Participants	Country: Egypt Number randomised: not stated Post‐randomisation dropouts: not stated Revised sample size: not stated Average age: not stated Females: not stated Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): not stated Alcohol‐related cirrhosis: not stated Viral‐related cirrhosis: not stated Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated Other causes for cirrhosis: not stated Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated Follow‐up in months: 0.25 Years of recruitment: 2014 Inclusion criteria First episode of SBP
Interventions	Participants were randomly assigned to two groups Group 1: cefotaxime (n = not stated) Further details: cefotaxime 2 gm twice/day (route and duration not stated clearly, but appears to be 5 days or 1 week) Group 2: ceftriaxone (n = not stated) Further details: ceftriaxone 2 gm once/day (route duration not stated clearly, but appears to be 5 days or 1 week) Total number of participants and number of participants in each group was not reported
Outcomes	None of the outcomes of interest were reported.
Notes	Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	High risk	Comment: a prepublished protocol was not available, but the authors do not report routinely measured clinical outcomes adequately.
Other bias	Low risk	Comment: no other bias was noted.